<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have compared the antileukemic activity of the investigational biotherapeutic agent B43-<z:mp ids='MP_0010998'>PAP</z:mp> to the antileukemic activities of the standard chemotherapeutic drugs <z:chebi fb="0" ids="28445">vincristine</z:chebi> (VCR), <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> (PDN), L-asparaginase (L-ASP) as single agents as well as in a 3-drug combination regimen ("VPL") using a <z:mp ids='MP_0002536'>SCID</z:mp> mouse model of human B-cell precursor (BCP) <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) </plain></SENT>
<SENT sid="1" pm="."><plain>When mice (N = 95) were challenged with 1 x 10(6) NALM-6 <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells, <z:hpo ids='HP_0000001'>all</z:hpo> of them died of disseminated <z:hpo ids='HP_0001909'>leukemia</z:hpo> with a median event-free survival (EFS) of 47 +/- 6 days </plain></SENT>
<SENT sid="2" pm="."><plain>B43-<z:mp ids='MP_0010998'>PAP</z:mp> was more active than VCR, PDN, or L-ASP and the two-drug combinations VCR + B43-<z:mp ids='MP_0010998'>PAP</z:mp>, PDN + B43-<z:mp ids='MP_0010998'>PAP</z:mp>, or L-ASP + B43-<z:mp ids='MP_0010998'>PAP</z:mp> were not significantly more active than B43-<z:mp ids='MP_0010998'>PAP</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The 120 days EFS outcome results were 46 +/- 13% for B43-<z:mp ids='MP_0010998'>PAP</z:mp> (Median EFS = 92 +/- 22 days), 0 +/- 0% for VCR (Median EFS = 49 +/- 1 days), 40 +/- 22% for PDN (Median EFS = 100 +/- 20 days), 0 +/- 0% for L-ASP (Median EFS = 41 +/- 1 days), 60 +/- 22% for VCR + B43-<z:mp ids='MP_0010998'>PAP</z:mp> (Median EFS = &gt;120 days), 60 +/- 22% for PDN + B43-<z:mp ids='MP_0010998'>PAP</z:mp> (Median EFS = &gt;120 days), and 50 +/- 25% for L-ASP + B43-<z:mp ids='MP_0010998'>PAP</z:mp> (Median EFS = 93 +/- 27 days), When mice (N = 61) were challenged with 5 x 10(6) NALM-6 cells, <z:hpo ids='HP_0000001'>all</z:hpo> of them rapidly died of disseminated <z:hpo ids='HP_0001909'>leukemia</z:hpo> with a median EFS of 37 +/- 3 days </plain></SENT>
<SENT sid="4" pm="."><plain>The 3-drug combination "VPL" (Median EFS = 75 +/- 23 days) was slightly less active than B43-<z:mp ids='MP_0010998'>PAP</z:mp> (Median EFS = 84 +/- 19 days) (P = 0.09) </plain></SENT>
<SENT sid="5" pm="."><plain>Notably, the combination of "VPL" with B43-<z:mp ids='MP_0010998'>PAP</z:mp> (i.e., VPLB) resulted in 100% survival </plain></SENT>
<SENT sid="6" pm="."><plain>By comparison, the combination of "VPL" with <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> (i.e., VPLD) (Median EFS = 69 +/- 31 days) was not more active than VPL </plain></SENT>
<SENT sid="7" pm="."><plain>To our knowledge, this preclinical study is the first to demonstrate the feasibility and superb antileukemic activity of immunochemotherapy using anti-CD19 immunotoxin in combination with the standard 3-drug combination "VPL" against BCP ALL </plain></SENT>
</text></document>